{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:05:01Z","timestamp":1771517101147,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04044-3","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T13:02:53Z","timestamp":1756558973000},"page":"963-973","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of cetuximab-based versus platinum-based chemoradiation in HNSCC: evidence from a meta-analysis of 10 randomized controlled trials"],"prefix":"10.1007","volume":"28","author":[{"given":"Tarun","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishu","family":"Kesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atindra Kumar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Chakrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjusha","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruhi","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esha","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-9846","authenticated-orcid":false,"given":"Manoj","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"2","key":"4044_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3181\/00379727-97-23777","volume":"97","author":"C Heidelberger","year":"1958","unstructured":"Heidelberger C, Griesbach L, Cruz O, Schnitzer RJ, Grunberg E. Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2\u2019-deoxyuridine on transplanted tumors. Exp Biol Med (Maywood). 1958;97(2):470\u20135.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"4044_CR2","volume":"19","author":"X Sun","year":"2024","unstructured":"Sun X, Wu L, Du L, Xu W, Han M. Targeting the organelle for radiosensitization in cancer radiotherapy. Asian J Pharm Sci. 2024;19(2): 100903.","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"4044_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/oxfordjournals.bmb.a070956","volume":"29","author":"GE Adams","year":"1973","unstructured":"Adams GE. Chemical radiosensitization of hypoxic cells. Br Med Bull. 1973;29(1):48\u201353. https:\/\/doi.org\/10.1093\/oxfordjournals.bmb.a070956.","journal-title":"Br Med Bull"},{"issue":"1","key":"4044_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tips.2017.11.003","volume":"39","author":"H Wang","year":"2018","unstructured":"Wang H, Mu X, He H, Zhang XD. Cancer radiosensitizers. Trends Pharmacol Sci. 2018;39(1):24\u201348.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4044_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","volume":"92","author":"JP Pignon","year":"2009","unstructured":"Pignon JP, le Ma\u00eetre A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4\u201314.","journal-title":"Radiother Oncol"},{"issue":"21","key":"4044_CR6","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","volume":"26","author":"M Machtay","year":"2008","unstructured":"Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4044_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"4044_CR8","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","volume":"21","author":"J Mendelsohn","year":"2003","unstructured":"Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21(14):2787\u201399.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4044_CR9","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1200\/JCO.1993.11.10.1873","volume":"11","author":"O Dassonville","year":"1993","unstructured":"Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993;11(10):1873\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4044_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.ijrobp.2003.07.010","volume":"58","author":"KK Ang","year":"2004","unstructured":"Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58(3):959\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"4044_CR11","first-page":"1935","volume":"59","author":"SM Huang","year":"1999","unstructured":"Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59(8):1935\u201340.","journal-title":"Cancer Res"},{"issue":"6","key":"4044_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/cbr.1999.14.451","volume":"14","author":"MN Saleh","year":"1999","unstructured":"Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14(6):451\u201363. https:\/\/doi.org\/10.1089\/cbr.1999.14.451.","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"4044_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567\u201378.","journal-title":"N Engl J Med"},{"issue":"19","key":"4044_CR14","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1056\/NEJMoa032641","volume":"350","author":"J Bernier","year":"2004","unstructured":"Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lef\u00e8bvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945\u201352.","journal-title":"N Engl J Med"},{"issue":"19","key":"4044_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","volume":"350","author":"JS Cooper","year":"2004","unstructured":"Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937\u201344.","journal-title":"N Engl J Med"},{"issue":"11","key":"4044_CR16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.oraloncology.2014.08.005","volume":"50","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Riboldi V, Borgonovo K, Ghilardi M, Cabiddu M, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol. 2014;50(11):1041\u20138.","journal-title":"Oral Oncol"},{"key":"4044_CR17","doi-asserted-by":"crossref","unstructured":"Wh TWS, Gx L. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis. Medicine (Baltimore) [Internet]. 2020 Sep 4 [cited 2025 Mar 2];99(36). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32899005\/","DOI":"10.1097\/MD.0000000000021785"},{"issue":"12","key":"4044_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.clon.2022.03.009","volume":"34","author":"M Swain","year":"2022","unstructured":"Swain M, Kannan S, Srinivasan S, Agarwal JP, Gupta T. Concurrent cetuximab-based bioradiotherapy versus cisplatin-based chemoradiotherapy in the definitive management of favourable biology human papillomavirus-associated oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Clin Oncol R Coll Radiol GB. 2022;34(12):786\u201395.","journal-title":"Clin Oncol R Coll Radiol GB"},{"issue":"10166","key":"4044_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"ML Gillison","year":"2019","unstructured":"Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40\u201350.","journal-title":"Lancet"},{"issue":"10166","key":"4044_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51\u201360.","journal-title":"Lancet"},{"issue":"30","key":"4044_CR21","first-page":"6","volume":"1","author":"K Al-Saleh","year":"2019","unstructured":"Al-Saleh K, El-Sherify M, Safwat R, Elbasmy A, Shete J, Hussein A, et al. Phase II\/III randomized controlled trial of concomitant hyperfractionated radiotherapy plus cetuximab (Anti-EGFR antibody) or chemotherapy in locally advanced head and neck cancer. Gulf J Oncolog. 2019;1(30):6\u201312.","journal-title":"Gulf J Oncolog"},{"issue":"4","key":"4044_CR22","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hed.27619","volume":"46","author":"M Berg","year":"2024","unstructured":"Berg M, Hansson C, Silander E, Bove M, Johansson L, Haugen Cange H, et al. A randomized study comparing the nutritional effects of radiotherapy with cetuximab versus cisplatin in patients with advanced head and neck cancer. Head Neck. 2024;46(4):760\u201371.","journal-title":"Head Neck"},{"issue":"3","key":"4044_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ijrobp.2020.02.637","volume":"107","author":"M Maddalo","year":"2020","unstructured":"Maddalo M, Borghetti P, Tomasini D, Corv\u00f2 R, Bonomo P, Petrucci A, et al. Cetuximab and radiation therapy versus cisplatin and radiation therapy for locally advanced head and neck cancer: long-term survival and toxicity outcomes of a randomized phase 2 trial. Int J Radiat Oncol Biol Phys. 2020;107(3):469\u201377.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"4044_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ijrobp.2016.10.011","volume":"97","author":"M Buglione","year":"2017","unstructured":"Buglione M, Maddalo M, Corv\u00f2 R, Pirtoli L, Paiar F, Lastrucci L, et al. Subgroup analysis according to human papillomavirus status and tumor site of a randomized phase II trial comparing cetuximab and cisplatin combined with radiation therapy for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2017;97(3):462\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4044_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106087","volume":"134","author":"R Hitt","year":"2022","unstructured":"Hitt R, Mes\u00eda R, Lozano A, Iglesias Docampo L, Grau JJ, Taberna M, et al. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer. Oral Oncol. 2022;134: 106087.","journal-title":"Oral Oncol"},{"issue":"5","key":"4044_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","volume":"34","author":"SM Magrini","year":"2016","unstructured":"Magrini SM, Buglione M, Corv\u00f2 R, Pirtoli L, Paiar F, Ponticelli P, Petrucci A, Bacigalupo A, Crociani M, Lastrucci L, Vecchio S, Bonomo P, Pasinetti N, Triggiani L, Cavagnini R, Costa L, Tonoli S, Maddalo M, Grisanti S. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. 2016;34(5):427\u201335. https:\/\/doi.org\/10.1200\/JCO.2015.63.1671.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4044_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7): e1000100.","journal-title":"PLoS Med"},{"issue":"7","key":"4044_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","volume":"31","author":"JL Lefebvre","year":"2013","unstructured":"Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853\u20139.","journal-title":"J Clin Oncol"},{"key":"4044_CR29","doi-asserted-by":"crossref","unstructured":"Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codec\u00e0 C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II\u2013III trial. Ann Oncol. 2017 Sep 1;28(9):2206\u201312.","DOI":"10.1093\/annonc\/mdx299"},{"key":"4044_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"4044_CR31","unstructured":"Risk of Bias 2 (RoB 2) tool | Cochrane Handbook for Systematic Reviews of Interventions Chapter 8, \u2018Assessing risk of bias in a randomized trial https:\/\/methods.cochrane.org\/risk-bias-2 [Last accessed August 7, 2025]"},{"key":"4044_CR32","unstructured":"Definition of all-cause mortality\u2014NCI Dictionary of Cancer Terms\u2014NCI [Internet]. 2011 [cited 2025 Mar 1]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/all-cause-mortality"},{"key":"4044_CR33","doi-asserted-by":"publisher","unstructured":"Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom? [Internet]. [cited 2025 Apr 23]. Available from: https:\/\/doi.org\/10.1200\/ADN.21.200751\/full","DOI":"10.1200\/ADN.21.200751\/full"},{"key":"4044_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8: 16.","journal-title":"Trials"},{"issue":"20","key":"4044_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12957-022-02835-4","volume":"22","author":"R Purwar","year":"2022","unstructured":"Purwar R, Ranjan R, Soni K, Pandey M, Upadhyay SK, Pai E, et al. Lymphadenectomy in ovarian cancers: a meta-analysis of hazard ratios from randomized clinical trials. World J Surg Oncol. 2022;22(20):367.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"4044_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4097\/kjae.2018.71.2.103","volume":"71","author":"E Ahn","year":"2018","unstructured":"Ahn E, Kang H. Introduction to systematic review and meta-analysis. Korean J Anesthesiol. 2018;71(2):103\u201312.","journal-title":"Korean J Anesthesiol"},{"issue":"1","key":"4044_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/ije\/31.1.88","volume":"31","author":"F Song","year":"2002","unstructured":"Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol. 2002;31(1):88\u201395.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"4044_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18040752","volume":"18","author":"Y Miyamoto","year":"2017","unstructured":"Miyamoto Y, Suyama K, Baba H. Recent advances in targeting the EGFR signaling pathway for the treatment of metastatic colorectal cancer. Int J Mol Sci. 2017;18(4): 752.","journal-title":"Int J Mol Sci"},{"key":"4044_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.614332","volume":"11","author":"S Ortiz-Cuaran","year":"2021","unstructured":"Ortiz-Cuaran S, Bouaoud J, Karabajakian A, Fayette J, Saintigny P. Precision medicine approaches to overcome resistance to therapy in head and neck cancers. Front Oncol. 2021;11: 614332.","journal-title":"Front Oncol"},{"issue":"3","key":"4044_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/gastro\/goaa026","volume":"8","author":"QH Li","year":"2020","unstructured":"Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep. 2020;8(3):179\u201391.","journal-title":"Gastroenterol Rep"},{"issue":"10","key":"4044_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0276497","volume":"17","author":"JH Park","year":"2022","unstructured":"Park JH, Kim MY, Choi IS, Kim JW, Kim JW, Lee KW, et al. Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients. PLoS One. 2022;17(10): e0276497.","journal-title":"PLoS One"},{"issue":"21","key":"4044_CR42","doi-asserted-by":"publisher","first-page":"5308","DOI":"10.3390\/cancers14215308","volume":"14","author":"A Saorin","year":"2022","unstructured":"Saorin A, Di Gregorio E, Buonadonna A, Miolo G, Corona G. The riddle of cetuximab-related skin toxicity: 1H-NMR sebum analysis revealed dynamic lipid alterations associated with skin toxicity development in metastatic colorectal cancer patients. Cancers. 2022;14(21):5308.","journal-title":"Cancers"},{"key":"4044_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/207084","volume":"2010","author":"N Makrilia","year":"2010","unstructured":"Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met-Based Drugs. 2010;2010: 207084.","journal-title":"Met-Based Drugs"},{"issue":"2","key":"4044_CR44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","volume":"90","author":"C Giro","year":"2009","unstructured":"Giro C, Berger B, B\u00f6lke E, Ciernik IF, Duprez F, Locati L, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009;90(2):166\u201371.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"1","key":"4044_CR45","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a phase I study of the CDK7-inhibitor samuraciclib. Nat Commun. 2023;14(1):4444.","journal-title":"Nat Commun"},{"issue":"1","key":"4044_CR46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.radonc.2010.11.009","volume":"98","author":"L Walsh","year":"2011","unstructured":"Walsh L, Gillham C, Dunne M, Fraser I, Hollywood D, Armstrong J, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 2011;98(1):38\u201341.","journal-title":"Radiother Oncol"},{"issue":"2","key":"4044_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jjco\/hyu196","volume":"45","author":"T Yokota","year":"2015","unstructured":"Yokota T, Onoe T, Ogawa H, Hamauchi S, Iida Y, Kamijo T, et al. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer. Jpn J Clin Oncol. 2015;45(2):183\u20138.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"4044_CR48","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1172\/JCI117840","volume":"95","author":"PA Wood","year":"1995","unstructured":"Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95(4):1650\u20139.","journal-title":"J Clin Invest"},{"issue":"22","key":"4044_CR49","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1186\/s12885-022-09708-9","volume":"7","author":"L Maahs","year":"2022","unstructured":"Maahs L, Ghanem AI, Gutta R, Tang A, Arya S, Al Saheli Z, et al. Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy. BMC Cancer. 2022;7(22):626.","journal-title":"BMC Cancer"},{"issue":"5","key":"4044_CR50","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.ijrobp.2021.12.141","volume":"112","author":"AI Ghanem","year":"2022","unstructured":"Ghanem AI, Maahs L, Gutta R, Tang A, Gilbert M, Arya S, et al. Does cetuximab reduce the risk of anemia in patients undergoing radiation therapy for head and neck cancers? Int J Radiat Oncol Biol Phys. 2022;112(5):e61\u20132.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4044_CR51","volume":"32","author":"K Jordan","year":"2024","unstructured":"Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Ruhlmann CH, et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents\u2014updated MASCC\/ESMO consensus recommendation. Support Care Cancer. 2024;32(1): 53.","journal-title":"Support Care Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04044-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04044-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:04:18Z","timestamp":1771513458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04044-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4044"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04044-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent"}}]}}